Emerging Paradigm for the Management of mNSCLC
2024 Updates on NSCLC Targeted Therapies: FLAURA2 Trial - Osimertinib + Chemo vs. Osimertinib Alone for Advanced EGFRm Disease
By
Yale Cancer Center
FEATURING
Pasi Janne
By
Yale Cancer Center
FEATURING
Pasi Janne
Disclaimer: On February 16, 2024, the FDA approved osimertinib (TAGRISSO®) with platinum-based chemotherapy for patients with la/mNSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
Comments 0
Login to view comments.
Click here to Login
